Welcome to our dedicated page for Citius Oncology SEC filings (Ticker: CTOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LYMPHIR’s journey from Phase 3 data to FDA approval is scattered across hundreds of pages of Citius Oncology (CTOR) SEC documents. Locating IL-2 receptor efficacy tables in a 10-K or confirming when executives file a Form 4 before a clinical update can be overwhelming.
Stock Titan’s AI solves that problem. The moment CTOR posts an 8-K material event, a quarterly earnings report 10-Q, or executive stock transactions Form 4, our platform delivers real-time alerts and plain-English summaries. Want the cash-burn trend hidden in note 7 of the latest Citius Oncology quarterly earnings report 10-Q filing? We surface it instantly. Need to understand Citius Oncology insider trading Form 4 transactions before the next financing? Our AI groups, tags, and explains them—no spreadsheet required.
- Annual report 10-K simplified: drill into pipeline risk factors, orphan-drug exclusivity periods, and reimbursement assumptions.
- 8-K material events explained: see exactly how new LYMPHIR trial data or HCPCS code updates may move the stock.
- Proxy statement executive compensation: tie bonuses to clinical milestones without sifting through compensation tables.
- Form 4 insider transactions real-time: track every director buy or sell related to upcoming oncology readouts.
Whether you’re asking, “How do I read the Citius Oncology 10-K?” or “Where can I find CTOR executive Form 4 filings?”—this page has the answers. Explore every Citius Oncology SEC filing explained simply, keep pace with CTOR earnings report filing analysis, and make informed decisions backed by AI-powered insight.
Citius Oncology director Eugene Myron Holuka acquired 300,000 restricted shares on 09/19/2025 and holds outstanding stock options totaling 275,000 shares. The restricted stock award was granted at no cash price and will vest in three substantially equal annual installments beginning one year after grant, subject to continued service. The reporting person also holds a $1.07 strike option for 125,000 shares (granted 12/12/2024, vesting 1/3 annually) and a fully vested $2.15 strike option for 150,000 shares. Following the reported transactions, the reporting person beneficially owns 300,000 shares and options on 275,000 shares directly.
Citius Pharmaceuticals, Inc. amended its Schedule 13D to reflect a registered direct offering on September 10, 2025 that issued 5,142,858 new common shares of Citius Oncology, Inc. After that issuance the reporting person, Citius Pharmaceuticals, Inc., beneficially owns 66,049,615 shares, representing approximately 79.1% of the issued and outstanding common stock based on a total of 83,513,442 shares. The filing states the reporting person has sole voting and dispositive power over those shares. The amendment updates prior Schedule 13D filings to give effect to the new issuance.
FAQ
What is the current stock price of Citius Oncology (CTOR)?
What is the market cap of Citius Oncology (CTOR)?
